Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. BARD1 Antibody

BARD1 Antibody

  • 中文名稱：
    BARD1兔多克隆抗體
  • 貨號：
    CSB-PA138883
  • 規(guī)格：
    ￥2024
  • 圖片：
    • Western blot analysis of extracts from HeLa cells, using BARD1 antibody.
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品名稱：
    Rabbit anti-Homo sapiens (Human) BARD1 Polyclonal antibody
  • Uniprot No.：
  • 基因名：
    BARD1
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Synthesized peptide derived from N-terminal of Human BARD1.
  • 免疫原種屬：
    Homo sapiens (Human)
  • 克隆類型：
    Polyclonal
  • 純化方式：
    The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA,WB
  • 推薦稀釋比：
    Application Recommended Dilution
    WB 1:500-1:3000
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能：
    E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.
  • 基因功能參考文獻(xiàn)：
    1. Study shows that tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemo- and radiotherapy because of upregulated BARD1 and BRCA1, which is caused by activated PI3K/AKT pathway. PMID: 29686231
    2. The results reveal new information for the manner in which full-length BRCA1 engages its binding partner, BARD1, under oxidative stress conditions. PMID: 28262780
    3. BARD1 RING domain is critical to BRCA1/BARD1 binding to nucleosomes and hence to ubiquitylation of histone H2A and also critical to transcriptional repression of BRCA1-regulated genes active in estrogen metabolism. PMID: 29367421
    4. BARD1delta binds more efficiently than BARD1 to telomere binding proteins and causes their depletion from telomeres, leading to telomere and chromosomal instability and tumor cell cycle arrest. PMID: 28030839
    5. BRCA1-BARD1 mutants with weakened RAD51 interactions show compromised DNA joint formation and impaired mediation of homologous recombination and DNA repair in cells; results identify a late role of BRCA1-BARD1 in homologous recombination, an attribute of the tumour suppressor complex that could be targeted in cancer therapy PMID: 28976962
    6. variants in BARD1 were associated with moderate risks of breast cancer. PMID: 28418444
    7. NPM1 downregulation by P-STAT5 is mediated by impairing the BRCA1-BARD1 ubiquitin ligase, which controls the stability of NPM1. In turn, decreased NPM1 levels led to suppression of p53 expression, resulting in enhanced cell survival. PMID: 28005077
    8. In MCF-7 cells BARD1 variants do vary considerably their cellular distribution and in their ability to influence apoptotic response to cisplatin. PMID: 27477900
    9. substitutions that create a structurally intact BRCA1/BARD1 heterodimer that is inactive in vitro with all E2 enzymes. Other substitutions in BRCA1 or BARD1 RING domains result in hyperactivity, revealing that both proteins have evolved attenuated activity. Loss of attenuation results in decreased product specificity, providing a rationale for why nature has tuned BRCA1 activity. PMID: 27977889
    10. Findings suggest that the study of AtROW1 in plant may provide a model for elucidating the functional mechanism of BARD1 in mammals. PMID: 27502904
    11. BRCA1-BARD1 ligase activity and subsequent SMARCAD1-dependent chromatin remodeling are critical regulators of DNA repair in cancer cells. PMID: 27239795
    12. Results suggest that BRCA1-associated RING domain protein 1 (BARD1) rs7585356 G>A polymorphism may be associated with nephroblastoma risk. PMID: 28161399
    13. BARD1 rs6435862 T>G and rs3768716 A>G single nucleotide polymorphisms contribute to increased susceptibility to neuroblastoma, especially for children at age >/=12 months in a Southern Chinese population. PMID: 26941572
    14. BRCA pathway germline mutation (in BRCA1, BRCA2 or BARD1 genes) was present in 10 of the 42 investigated triple-negative breast cancer patients rendering them susceptible to homologous recombination deficiency. PMID: 26010302
    15. Study presents four different pathogenic BARD1 variants identified in ovarian cancer patients. Three of them result in incorrect splicing of the corresponding exons, which may prompt expression of specific BARD1 isoforms and carcinogenesis. PMID: 26329992
    16. Suggest BARD1 as a driver of proliferation and of pulmonary fibrosis pathogenesis. PMID: 26415510
    17. a role for the BRCT domain in stimulating BARD1 nuclear export and mitochondrial localization, and in assembling mitochondrial BARD1/p53 complexes to regulate specific activities such as apoptotic function. PMID: 26022179
    18. Mutations do not contribute substantially (>> 10% of the total BARD1 mutations) to BARD1 sequence variation and, subsequently, to familial breast and/or ovarian cancer aggregation. PMID: 25994375
    19. BARD1 interacts with H3K9me2 through HP1 and plays a critical role in retention of a BRCA1/BARD1 complex at the site of DNA damage. PMID: 25634209
    20. FOXK2 might act as a negative regulator of ERalpha, and its association with both ERalpha and BRCA1/BARD1 could lead to the down-regulation of ERalpha transcriptional activity, effectively regulating the function of ERalpha. PMID: 25740706
    21. Increased expression of the BARD1 protein, with its ubiquitin ligase function, was associated with significantly improved overall and disease-free survival, which has yet to be documented for ACC. PMID: 25657202
    22. BARD1 long non-coding RNA is overexpressed in neoplasms. PMID: 25008968
    23. HDACi (histone deacetylase inhibitor) Vorinostat reduces BARD1 mRNA levels by increasing miR-19a and miR-19b expression levels. PMID: 24349422
    24. BARD1 is frequently overexpressed in brain metastases from breast cancer and may constitute a mechanism to overcome reactive oxygen species-mediated genotoxic stress in the metastatic brain. PMID: 24948741
    25. SNP sites rs2229571 and rs1048108 of BARD1 are associated with a lower risk of breast cancer but not rs2070094. PMID: 23966609
    26. BARD1 is a major gentic contributor to neuroblastoma. PMID: 23222812
    27. Data indicate that four nsSNPs, rs4986841, rs111367604, rs13389423 and rs139785364, were identified as deleterious, reducing the protein stability of BARD1, and these SNPs can be used for the larger population-based studies of female cancers. PMID: 23056176
    28. SNPs of Pro24Ser(C/T), Arg378Ser (G/C) and Val507Met (G/A) of BARD1 gene are associated with significantly decreased risk of early-onset breast cancer in Uygur women in Xinjiang. PMID: 22883453
    29. It is concluded that a proportion of patients with therapy related myeloid neoplasms carry cancer susceptibility mutations,including BARD1 mutations, which is likely to contribute to therapy related leukaemogenesis. PMID: 22652532
    30. Our results suggest that BARD1 557Ser and XRCC3 241Met may play roles in BC risk in women with a strong family history of breast cancer (BC). PMID: 22544576
    31. Single-nucleotide polymorphisms in BARD1 gene is associated to neuroblastoma. PMID: 22328350
    32. BARD1 mutations may be regarded as cancer risk alleles and warrant further investigation to determine their actual contribution to non-BRCA1/2 breast and ovarian cancer families. PMID: 21344236
    33. BARD1 isoforms might be involved in tumor initiation and invasive progression and might represent a novel prognostic marker for non-small cell lung cancer. PMID: 21815143
    34. our findings identify BARD1beta as an oncogenic driver of high-risk neuroblastoma tumorigenesis PMID: 22350409
    35. the BRCA1/BARD1 ubiquitin ligase complex was found to enhance SAFB protein expression and induce Tel2 nuclear translocation PMID: 21950761
    36. Data suggest that BARD1 regulation is an important pathway in colon cancer and that the BARD1 full-length protein may be a useful marker to improve risk stratification in colon cancer patients. PMID: 21693656
    37. suggests that BARD1 Cys557Ser mutation is not associated with increased breast cancer risk PMID: 21809034
    38. Genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. PMID: 21393566
    39. Data show that inhibition of BRCA1/BARD1 downregulation is accompanied by the unscheduled recruitment of both proteins to chromatin along with Rad51. PMID: 21103343
    40. a tumor with homozygous deletion of BARD1 displayed a BRCA1-mutated expression profile; BARD1 might be a breast cancer susceptibility gene with BRCA1-like expression profile PMID: 20842729
    41. Common variations in BARD1 contribute to the etiology of the aggressive and most clinically relevant subset of human neuroblastoma. PMID: 19412175
    42. analysis of cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families PMID: 20077502
    43. BRCA1 and BARD1 are required for estrogen receptor alpha ubiquitination and degradation, and repression of either one leads to ERalpha accumulation, suggesting a feedback loop between BRCA1-BARD1 and estrogen receptor alpha PMID: 20060929
    44. The science behind BARD1 and its role in breast and ovarian cancer is explained in this article. PMID: 19959210
    45. Four genes encoding BRCA1-interacting proteins were analyzed in a cohort of 96 breast cancer individuals from high-risk non-BRCA1/BRCA2 French Canadian families. PMID: 19197335
    46. BARD1 phosphorylation, expression and localisation patterns are regulated in the nucleus and at mitochondria in response to different forms of DNA damage. PMID: 19796682
    47. Germline mutations of BARD1 have been detected in hereditary breast and breast/ovarian cancers negative for BRCA1 and BRCA2 alterations. PMID: 11807980
    48. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export PMID: 11925436
    49. Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase. PMID: 11927591
    50. It is structurally homologous to BRCA1 (it shares the conserved RING finger and BRCT domains); may be involved in tumor suppression because BARD1-BRCA1 complexes in ubiquination of RNA Pol II and BARD1 interacts with CstF-50 (inhibiting mRNA processing). PMID: 11943588

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Nucleus. Note=During S phase of the cell cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 952

    OMIM: 601593

    KEGG: hsa:580

    STRING: 9606.ENSP00000260947

    UniGene: Hs.591642